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Suramin inhibits immune responses and protects cells against inﬂammatory cell injury. However, little is
known about its mechanisms. Using an in vitromodel of glomerular mesangial cell (MC) lysis induced by
antibodies plus complement, we investigated the potential protective effects and mechanisms of suramin
on immunologic cell injury. Exposure of rat MCs to anti-Thy-1 antibody plus complement or anti-MC
rabbit serum caused complement-dependent cell lysis, which was blocked by suramin and its struc-
tural analogue NF023 and NF049, but not by PPADS, an antagonist of purinergic receptors. Addition of
exogenous ATP also failed to affect MC lysis. Further analysis revealed that suramin interfered with
antibody binding to cell membrane antigens and suppressed antibody-induced phosphorylation of
several proteins, including p38. Inhibition of p38 with chemical inhibitor signiﬁcantly attenuated cell
injury. Collectively, our results indicate that suramin protects cells against antibody-initiated and
complement-dependent cell injury through inhibition of antibody binding to cell surface antigens and
suppression of p38 activation. Our study thus provides novel mechanistic insights into the actions of
suramin and suggests that suramin might be used to treat certain immune diseases.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Antibody-triggered and complement-mediated cell injury con-
tributes to the initiation and progression of glomerular nephritis.
One of the well-used animal models for investigation of mesangial
proliferative glomerulonephritis is Thy-1 nephritis (1e3). In this
model, the injected anti-Thy-1 antibody binds to Thy-1 molecules
in glomerular mesangial cells (MCs) and causes complement acti-
vation and complement-mediated MC lysis, which is followed by
inﬂammatory cell inﬁltration, MC proliferation and matrixent assay; Igs, immunoglob-
ane attack complex; MCs,
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. Production and hosting by Elseexpansion, typical pathological features of proliferative glomeru-
lonephritis. Anti-Thy-1 antibody-induced MC injury has been
extensively used for exploring mechanisms of inﬂammatory cell
injury and ﬁnding effective therapeutic solutions.
Suramin is an anti-protozoal drug developedmore than 90 years
ago. It has miscellaneous pharmacological effects, including anti-
virus, anti-inﬂammation and anti-tumor actions, and has been
used for treatment of a wide range of diseases (4e9). Suramin in-
hibits inﬂammatory responses and protects cells from inﬂamma-
tory cell injury (5, 7, 10e14). It affects many immune responses,
including inhibition of cell adhesion, cytokine production and cell
reactions to many inﬂammatory stimuli (10, 12, 15e18). It also in-
hibits complement-mediated lysis of red blood cells (19). Currently,
the mechanisms involved in these actions of suramin are still
obscure.
One of the interesting effects of suramin is that it interrupts the
interactions between cell surface proteins and a variety of mole-
cules or pathogens (20e22). It inhibits binding of cytokines,
growth factors, and inﬂammatory mediators to cell receptors and
suppresses their biological actions (4, 12, 15, 16, 22e25). It alsovier B.V. This is an open access article under the CC BY-NC-ND license (http://
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more, it suppresses multiple membrane channels and protects
cells against pore-forming toxin-elicited cell injury (13). The ef-
fects of suramin on diverse molecular events occurring at the cell
surface promoted us to speculate that suramin might affect anti-
body binding to cell-surface antigens and prevent cell injury
induced by the lethal pore-like “membrane attack complex” (MAC)
of complement. Using an in vitro model of glomerular MC lysis
induced by antibodies and complement, we addressed this
possibility.
Here we present our results showing that suramin protected
MCs from complement-mediated cell lysis through multiple
mechanisms. Our study thus indicates that suramin holds promise
for treatment of certain immune diseases.2. Materials and methods
2.1. Materials
Anti-phosphoserine/threonine and anti-phosphotyrosine anti-
bodies were purchased from BD transduction laboratory (BD
Transduction Laboratory, San Diego, CA, USA). NF023 and NF449
were bought from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Calcein AM was obtained from Invitrogen (Tokyo, Japan). Dyna-
beads protein A and protein G Mag Sepharose were from Novex in
life technologies (Norway) and GE Health care (UK), respectively.
HRP-conjugated anti-rabbit or mouse IgG and anti-b-actin anti-
bodies were purchased from Cell Signaling, Inc. (Beverly, MA, USA).
Anti-Thy-1 monoclonal antibody 1-22-3 was kindly gifted by Dr.
Kawachi (Institute of Nephrology, Niigata University). Suramin,
pyridoxalphosphate-6-azopheny1-20,40-disulfonic acid (PPADS),
and all other reagents and antibodies were purchased from Sigma
(Tokyo, Japan).2.2. Rabbit serum
Rabbit blood was collected by ear artery bleeding from the
Japanese White (JW-NIBS) Strain Rabbit. The blood was allowed to
clot for 30 min at room temperature. The serum was obtained and
stored at 80 C until use. For inactivation of complement, the
serumwas heated at 56 C for 30 min. All animal experiments were
approved by the animal experiment committee of the University of
Yamanashi and performed in accordance with relevant guidelines
and regulations.2.3. Cells
Rat MCs were obtained from the outgrowth of the isolated
glomeruli, as described previously (26, 27). For maintenance and
passage, cells weremaintained in DMEM (Gibco-BRL, Gaithersburg,
MD, USA) supplemented with 5% FBS. For experiments, cells were
cultured with DMEM containing 1% FBS and various stimuli.2.4. Calcein AM-propidium iodide (PI) cell-survival assay
Cells were exposed to stimuli for the indicated time intervals
and cell survival was determined by the Calcein AM/PI live/dead
assay as described previously (28). Live cells exhibit staining for
calcein-AM activity (green ﬂuorescence), whereas dead cells stain
positive for PI (red ﬂorescence).2.5. Cellular enzyme-linked immunosorbent assay (ELISA) for
detection of cell surface bound antibodies
MCswere seeded into 96-well at the density of 15,000 cells/well
in DMEM/F12 with 1% FBS. After 24 h, the cells were incubated with
heat-treated rabbit serum or anti-Thy-1 antibody in the presence or
absence of suramin at 37 C for 1 h. After washing with culture
medium, the cells were exposed to HRP-conjugated anti-rabbit or
mouse IgG for 1 h at room temperature. The immune complexes are
detected by the subsequent substrate reaction using a ready-to-use
3,30,5,50-Tetramethylbenzidine (TMB) solution in a commercial kit
for cell proliferation assay from Roche (Roche Life Sciences, Bran-
ford, Connecticut, USA). The reaction product is quantiﬁed by
measuring the absorbance using a scanning multi-well spectro-
photometer (ELISA reader).
2.6. Precipitation of membrane-bound antibodies
MCs were incubated with 0.5% heat-treated rabbit serum in the
presence of different concentrations of suramin at 37 C for 1 h.
After washing with culture medium, total cellular protein was
extracted by suspending the cells in RIPA lysis buffer. Lysates were
incubated on ice for 30 min with intermittent mixing and then
centrifuged at 15,350  g for 10 min at 4 C. Supernatant was
recovered and determined for protein concentration using the
Micro BCA Protein Assay Kit (Thermo Fisher Scientiﬁc, Waltham,
MA). Same amount of lysates in 200 ml RIPA was incubated with a
mixture of protein A and G beads in a rotator at 4 C overnight. The
pellet was washed with 500 ml RIPA for 3 times, and re-suspended
with 50 ml 2 SDS sample buffer containing 5 mM DTT. After heat
treatment at 95e100 C for 5 min, supernatants were collected and
loaded on a 10% gel for SDS-PAGE and Western immunoblotting of
cell bound-immunoglobulins (Igs) as described above.
2.7. Evaluation of membrane permeability and integrity using
calcein AM
Calcein AM was used to evaluate the integrity of cytoplasmic
membrane as previously described (13). Brieﬂy, cells were pre-
loaded with 10 mM calcein AM for 1 h at 37 C in culture medium.
After washing once with the culture medium, cells were exposed to
rabbit serum in the presence or absence of p38 inhibitor SB203580
for the indicated time intervals. The ﬂuorescent image was visu-
alized and captured using an Olympus IX71 inverted ﬂuorescence
cube.
2.8. Immunoﬂuorescence
Mesangial cells were exposed to 1% heat-treated rabbit serum in
the presence or absence of suramin. The cells were then rinsedwith
PBS, ﬁxed with 3% paraformaldehyde, and stained with tetrame-
thy1 rhodamine B isothiocyanate-conjugated anti-rabbit immu-
noglobulin G (Dako, Glostrup, Denmark) for 1 h. After washed with
PBS, cells were observed under IFmicroscope and positive IF signals
in MCs were captured using a CCD camera attached to an Olympus
BX50 microscope.
2.9. Lactate dehydrogenase (LDH) release assay
Cytotoxicity was evaluated by the release of LDH using a LDH
cytotoxicity detection kit (Takara Bio, Inc., Otsu, Shiga, Japan), as
described previously (13). Brieﬂy, cells in 96-well culture plate
were exposed to various stimuli for the indicated time periods.
Culture medium was collected and measured for LDH activity. LDH
release was calculated and expressed as percentage of total release.
Fig. 1. Induction of rat mesangial cell (MC) lysis by rabbit serum. (A) Induction of MC
lysis by rabbit serum. Mesangial cell were exposed to Thy-1 antibody in the presence of
different concentrations of normal or heat-treated rabbit serum for 3 h. After that,
culture supernatants were collected and assayed for LDH activities. (B) Binding of
rabbit Igs to cultured MCs. MCs were exposed heat-treated rabbit serum or left un-
treated for 1 h. After washing with PBS, cells were stained with rhodamine-labeled
anti-rabbit IgG for an additional 1 h. The ﬂuorescent signals in MCs were photo-
graphed. (C) Presence of anti-MC antibodies in the rabbit serum. Triplicate cellular
lysates of MCs were separated through SDS-gel, transferred to PVDF membrane and
immunoblotted using either the rabbit serum or Thy-1 antibody as the primary anti-
bodies. Afterward, the blots were reacted with HRP-labeled anti-rabbit or anti-mouse
antibodies. Note that two of the bands recognized by rabbit serum were localized at
the same position as detected by anti-Thy-1 antibody. The predicted molecular weight
of Thy-1 is 17 kDa.
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Total cellular protein was extracted by suspending the pre-
washed cells in SDS lysis buffer (62.5 mM TriseHCl, 2% SDS,
10% glycerol) together with freshly added proteinase inhibitor
cocktail (Nacalai Tesque, Kyoto, Japan). Lysates were incubated on
ice for 30 min with intermittent mixing and then centrifuged at
15,350  g for 10 min at 4 C. Supernatant was recovered and
determined for protein concentration using the Micro BCA Pro-
tein Assay Kit (Thermo Fisher Scientiﬁc, Waltham, MA). Western
blot was performed by the enhanced chemiluminescence system
(26, 27). Brieﬂy, extracted cellular proteins were separated by
polyvinylidine diﬂuoride membranes. After blocking with 3% BSA
in TBS, the membranes were either probed directly with HRP-
conjugated anti-rabbit or mouse IgG (Cell Signaling; Beverly,
MA, USA) for 1.5 h at room temperature or at 4 C overnight or
with the primary antibodies and then with the HRP-labeled
second antibodies. After washing, the bands were visualized by
the enhanced chemiluminescence system (Nacalai Tesque). The
chemiluminescent signal is captured with a Fujiﬁlm luminescent
image LAS-1000 analyser (Fujiﬁlm, Tokyo, Japan) and quantiﬁed
with the NIH Image J software (http://rsb.info.nih.gov/ij). To
conﬁrm equal loading of proteins, the membranes were probed
for b-actin.
2.11. Statistical analysis
All datawere presented as mean ± SE. Differences of two groups
were tested by Student's t test. When more than two groups were
compared, one-way ANOVA with Dunnett test were used. P values
less than 0.05 were considered signiﬁcant.
3. Results
3.1. Rabbit serum induces antibody-triggered and complement-
dependent glomerular MC lysis
To establish cell model of Thy-1 antibody-induced MC lysis, we
have exposed rat MCs to monoclonal anti-Thy-1 antibody in the
presence of different concentrations of rabbit serum as a source of
complement. As expected, this treatment led to a complement-
dependent MC cell death, as evidenced by the increased LDH
release and its abolishment by heating the serum at 56 C for
30 min (Fig. 1A). Unexpectedly, the control serum also elicited cell
death in a way similar to Thy-1 antibody plus serum. These results
pointed to the existence of anti-MC antibodies in the serum. To
conﬁrm this, we incubated MCs with heat-treated rabbit serum
and immunostained for the presence of rabbit Igs bound to cell
membrane. Fig. 1B shows that there were abundant rabbit Igs at
MC surface. Consistently, immunoblotting of MC lysates using
rabbit serum as the primary antibody revealed that the serum
reacted with several MC proteins. Intriguingly, two of them were
localized at the same position as those recognized by monoclonal
anti-Thy-1 antibody (Fig. 1C). These results thus indicate that
rabbit serum used in this investigation contained naturally
occurred anti-MC antibodies and elicited complement-dependent
MC death.
3.2. Suramin suppresses the rabbit serum-induced MC lysis
To determine whether suramin might protect MCs against the
complement-induced cell injury, we examined the rabbit serum-
induced cell lysis in the presence or absence of suramin. As
shown in Fig. 2A, incubation of MCs with the rabbit serum caused
complement-dependent cell death, as revealed by the loss ofnormal cell morphology and appearance of cell debris under mi-
croscopy. In the presence of suramin, however, these changes
were largely blocked. Consistently, suramin also prevented the
occurrence of PI-positive red cells, indicative of dead cells in live/
Fig. 2. Suramin suppresses the rabbit serum-mediated MC cell lysis. (A) Effect of suramin on rabbit serum-induced cell shape change. MCs were pretreated with 300 mM suramin for
30 min before exposing to 3% heat-treated or untreated rabbit serum for an additional 3 h. Afterward, cell morphology was photographed (B) Live/dead staining of rabbit serum-
treated cells. Cells were either left untreated (a) or treated with rabbit serum in the absence (b) or presence of 200 (c) or 300 mM (d) suramin for 1 h. The viability of cells was
determined using calcein (green) and PI (red) staining. (C) Effect of suramin on the rabbit serum-induced MC lysis. MCs were exposed to the indicated concentrations of normal or
heat-treated rabbit serum in the presence of 300 mM suramin (C) or 3% normal rabbit serum in the presence of different concentrations of suramin (D). Cellular supernatants were
collected and assayed for LDH activities. Data shown are mean ± SE (n ¼ 4). **P < 0.01 vs. zero control; #P < 0.01 vs. untreated control in C. *P < 0.05; #P < 0.01 vs. zero control in C.
(E) Inhibition of the rabbit serum-induced MC lysis by suramin analogues. MCs were exposed to 3% rabbit serum in the presence of absence of 300 mM suramin, NF449, or NF023 for
3 h. (F) Effect of P2 purinoceptor antagonist PPADS and exogenous ATP on rabbit serum-induced MC lysis. MCs were incubated with 3% rabbit serum in the presence or absence of
300 mM suramin, 30 mM PPADS or 300 mM ATP for 3 h. Data shown are mean ± SE (n ¼ 4). #P < 0.01 vs. control.
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suramin on cell death was concentration-dependent, as shown by
LDH release. At concentrations over 200 mM, suramin almost
completely blocked the rabbit serum-initiated cell death
(Fig. 2C, D).
In further support of a role of suramin, suramin analogue NF449
and NF023 (29, 30) also signiﬁcantly abrogated complement-
induced MC lysis (Fig. 2E). Given that suramin is a well-known
antagonist of purinergic receptors and that P2X receptorstimulation has been reported to amplify complement-induced
hemolysis (31), we therefore determined the possible involve-
ment of P2 purinoceptor in the effect of suramin. To this end, we
compared the effect of suramin with other P2 purinoceptor
antagonist, PPADS (32). Fig. 2F shows that PPADS did not affect the
serum-induced cell death. Furthermore, activation of purinergic
receptors with ATP also failed to inﬂuence the toxic effect of the
serum. These observations thus excluded an implication of P2 re-
ceptor in the protective effects of suramin.
Fig. 3. Suramin blocks the binding of rabbit serum and anti-Thy-1 antibody to MCs. (A) Inﬂuence of suramin on binding of rabbit serum to cell surface proteins. MCs were incubated
with 1% heat-treated rabbit serum for 1 h in the presence or absence of 300 mM suramin. The presence of rabbit Igs in cell surface was detected with rhodamine-labeled anti-rabbit
IgG. Note the binding to rabbit serum to MC and its prevention by suramin. (B, C) Prevention of rabbit Ig binding to MC surface protein by suramin. MCs were either left untreated or
exposed to 1% heat-treated rabbit serum (B) or 0.5 mg/ml Thy-1 (C) in the presence or absence of 300 mM suramin for 1 h. After washing, cellular lysates were extracted and detected
for the presence of membrane-bound Igs. Note that the positive bands were only detected in the serum and anti-Thy-1 antibody-pretreated cells (lane 3 and lane 4), but not in the
control cells (lane 1 and 2). b-actin was used as loading control. (D) MCs were either left untreated or exposed to 0.5% heat-treated rabbit serum or 0.5 mg/ml Thy-1 in the presence
or absence of the indicated concentrations of suramin. Cellular lysates were extracted. Igs in the lysates were precipitated using a protein A/G mix magnetic bead, separated with
SDS-page and immunoblotted with a HRP-labeled anti-rabbit or antiemouse antibodies. (E, F). Detection of cell membrane-bound Igs using Cellular Elisa. Cells in 96-well plate were
exposed to 0.5% heat-treated rabbit serum or 0.25 mg/ml anti-Thy-1 antibody in the presence or absence of the indicated concentration of suramin. Igs binding to the cell surface
were detected using Cellular ELISA. The results were expressed as percent of control. Data shown are mean ± SE (n ¼ 4). *P < 0.05 vs. zero control.
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antigens
To determine the mechanisms underlying the protective effects
of suramin, we examined the inﬂuence of suramin on binding of Igs
to MC surface. IF staining using rabbit serum as ﬁrst antibody
revealed a positive binding of rabbit immunoglobulins to MCs, as
evidenced by the positive immunoﬂuorescence in MCs. In the
presence of suramin, the ﬂuorescent intensity was greatly reduced
(Fig. 3A).
We also immunodetected cell surface bound rabbit Igs using
Western blot analysis. For this purpose, MCs were preincubatedwith heat-treated rabbit serum or anti-Thy-1 antibody for 1 h and
cell lysate were collected for detection of the presence of Igs. As
shown in Fig. 3B and C, there were no reactive bands in cellular
lysates obtained from control cells (lane 1 and 2), whereas cellular
proteins from rabbit serum or thy-1 antibody-pretreated cells
reacted with anti-rabbit or anti-mouse antibody. There were
several positive bands in the blots (lane 3 and 4). In the presence of
suramin, the intensity of the bands were greatly reduced. The re-
sults indicate that the binding of rabbit serum or anti-Thy-1 anti-
body to cell surface antigens are inhibited by suramin.
To clearly demonstrate that suramin suppressed Ig binding
to cell membrane, we precipitated Igs from the cellular lysates
Fig. 4. Suramin inhibits rabbit serum-induced phosphorylation of tyrosine and threonine residues in MCs. MCs were treated with 3% rabbit serum for the indicated time intervals (A, C)
or 30 min in the presence or absence of 300 mM suramin (B, D). Cellular protein was subjected to Western blot analysis of the levels of phospho-tyrosine (A, B) or phospho-serine/-
theronin proteins (C, D). Note the obviously reduced levels of tyrosine and threonine phosphorylation in the presence of suramin at the marked location.
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that suramin inhibited the rabbit Ig and anti-Thy-1 bindings to
cells in a concentration-dependent pattern. Of note, we only
detected one bands using the anti-rabbit and anti-mouse anti-
bodies, which was localized at the molecular weight around
55 kDa, corresponding to the reported MW of heavy chain
of Igs.
The inhibitory effect of suramin on Ig binding to cell surface
antigen was also conﬁrmed using cellular ELISA. In the presence of
suramin, the binding of rabbit serum and anti-Thy-1 antibody to
cell membrane was signiﬁcantly prevented (Fig. 3E and F). These
results thus indicate that suramin inhibits antibody binding to cell
surface antigens.3.4. Suramin inhibits serum-induced protein phosphorylation
The rabbit serum-induced cell deathwas preceded by a cell shape
change, including cell shrinkage and detachment from the culture
plate. Given that phosphorylation of structural and functional pro-
teins controls cell shape, cell structure and cell survival (33, 34), we
therefore examined the inﬂuence of suramin on rabbit serum-
induced protein phosphorylation. Incubation of MCs with rabbit
serum caused a time-dependent increase in phosphoproteins at the
MW around 28, 50, 75 and 100 for tyrosine and 50, 80 and 110 for
serine/threonine (Fig. 4A and C). Interestingly, heated rabbit serum
also induced protein phosphorylation, suggesting that the induction
was not caused by complement. In the presence of suramin, the band
intensity was greatly reduced, especially at the molecular weight
Fig. 5. p38 contributes to antibody-induced cell lysis. (A, B) Induction of cell lysis by rabbit serum. MCs were exposed to different concentrations of normal or heated rabbit serum for
1 h. Cell morphology were photographed (A) and LDH activity in the supernatants was measured (B). Data shown in B are mean ± SE (n ¼ 4, **P < 0.01 vs zero control; #P < 0.01 vs
unheated serum). (C) Cells preloaded with calcein were exposed to normal or heated rabbit serum for 3 h. Note the change of cell morphology and loss of calcein-positive green cells
following serum treatment. (D, E) Prevention of serum-elicited cell lysis by p38 inhibitor SB203580. MCs were exposed to 5% rabbit serum in the presence or absence of 300 mM
suramin or 10 mM SB203580 for 1 h. Cell viability were determined through the loss of calcein-positive cells (D) and LDH releases (E). Data shown in E are mean ± SE (n ¼ 4, *P < 0.01
vs control).
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(Fig. 4B and D). These data suggest that suramin inhibits antibody-
triggered phosphorylation of several cellular proteins.
3.5. Suramin inhibits serum-induced cell death partially through
suppression of p38
The suppression of protein phosphorylation by suramin
promoted to test whether suramin affected activation of mol-
ecules that are implicated in antibody- and complement-
induced cell injury. Given several reports show that p38 is
critically involved in complement-induced cell death (35, 36),
we therefore determined that inﬂuence of suramin on p38
activation. First, we conﬁrmed that p38 was critically involved
in cell injury under our experimental settings. In this study, wehave used the disappearance of the ﬂuorescence of preloaded
calcein as a parameter of cell survival. As shown in Fig. 5, the
induction of cell death by rabbit serum caused cell shape
change, LDH release and disappearance of calcein-positive
green cells (Fig. 5A to C). In the presence of suramin or p38
inhibitor SB203580, the cell death was signiﬁcantly suppressed
(Fig. 5D and E).
We then moved to examine the inﬂuence of suramin on p38
activation. Incubation of MCs with the rabbit serum caused a rapid
elevation in p38 phosphorylation (Fig. 6A). Intriguingly, suramin
inhibited p38 activation induced by both heat-treated and -un-
treated serum (Fig. 6B). Furthermore, it also reduced basal level of
p38 phosphorylation (Fig. 6B and C). These results indicate that
suramin interferes with p38 activation at both basal and serum-
stimulated situations.
Fig. 6. Suramin suppresses rabbit serum-induced activation of p38. (A) Induction of p38
phosphorylation by the rabbit serum. MCs were incubated with 3% rabbit serum for
the indicated time. The cellular lysates were subject to Western blot analysis of the
level of phospho-p38. b-actin was used as loading control. (B) Effect of suramin on
rabbit serum-elicited p38 activation. MCs were stimulated with heat-treated or un-
treated rabbit serum for 30 min in the presence or absence of 300 mM suramin. (C)
Densitometric analysis of the blot in (B). The intensity of p38 signal in (B) was
measured using NIH image software. The level of phosphor-p38 was expressed as fold
induction relative to untreated control (mean ± SE, n ¼ 4). *P < 0.05, #P < 0.01 vs.
respective control.
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stimuli
The suppression of p38 activation at basal level suggested that
suramin regulated p38 through mechanisms independent of anti-
body stimulation. To further conﬁrm this point, we examined the
time- and concentration-effect of suramin on p38. Fig. 7A and B
show that suramin suppressed p38 in a time- and concentration-
dependent manner.
We also the inﬂuence of suramin on p38 activation induced by
H2O2 and puromycin, which we have previously reported to induce
p38 through induction of oxidative stress. Suramin similarly sup-
pressed H2O2 and puromycin-triggered p38 activation (Fig. 7C to F).
These observations indicate that suramin suppressed p38
activation.4. Discussion
In this study, we demonstrated that suramin prevented antibody-
triggered and complement-dependent lysis of nucleated cells
in vitro. Furthermore, we provided evidences that suramin interfered
with antibody binding to cell surface antigens and suppressed p38
activation. Our study thus provides novel mechanistic insights into
the inhibitory effects of suramin on immune responses and suggests
that suramin could be exploited to treat certain immune diseases.
At the beginning of this investigation, we have used rabbit serum
as a source of complement for Thy-1 antibody-induced MC lysis.
Unexpectedly, in two of three batches of rabbit serums tested, the
sera themselves potently elicited MC lysis. Further analysis using IF
staining, western blot analysis and cellular Elisa revealed that the
serum contained antibodies against MC surface antigens. Some of
epitopes recognized by serum could be functionally important
because exposure of cells to complement-inactivated serum elicited
phosphorylation of several proteins at tyrosine and/or threonine
sites. The heated serum also activated p38, a signaling molecule that
mediates a variety of cell responses to multiple stimuli (37, 38).
Intriguingly, one of the proteins reacted with the rabbit serum was
localized at exactly the same position of Thy-1. Previous studies have
characterized Thy-1 as a signal molecule mediates anti-Thy-1 anti-
body induced activation of several signaling pathways, including
mitogen activated protein kinases pathway (MAPKs) (39). Currently,
the reasons for the presence of naturally occurred anti-MC anti-
bodies in the rabbit serum are unclear. Given that the serum
simultaneously provided antibodies and complement required for
induction of MC lysis and induced cell death to the extent compa-
rable to Thy-1 antibody, we have used the serum for most of the
experiments. Suppression of both serum- and anti-Thy-1-initiated
MC lysis by suramin indicate that the effect of suramin was not
antibody- and/or antigen-speciﬁc.
Suramin inhibits inﬂammatory responses in a variety of exper-
imental conditions (10, 12, 15e18). It inhibits complement-
mediated red blood cell lysis and has been considered as an in-
hibitor of complement (19, 40e42). Several previous studies indi-
cated that suramin potently inhibits complement activation
through affecting C1 binding and various other steps in the com-
plement activation sequence, possibly through inhibition of protein
to protein interaction and esterase (40, 42, 43). Antibody-triggered
complement-dependent cell lysis involves many processes,
including antibody binding to cell surface antigens, subsequent
activation of complement via the classic pathway and formation of
the “membrane attack complex” of C5-9, and induction of cell lysis.
Besides its actions on complement activation, the protective effect
of suramin could also be achieved through blocking antibody
binding to antigens and/or affecting signaling mechanisms that are
pivotally implicated in antibody/complement-elicited cell injury. In
this study, we revealed, for the ﬁrst time, that suramin weakened
antibody binding to cell surface epitope. Currently, the mechanisms
by which suramin inhibited Igs binding to cell membrane are still
unclear. Suramin has been reported to interfere with many in-
teractions that occur at cell surface, including cell to cell and bac-
teria/virus to cell adhesion, interaction between cell surface
adhesion molecules, as well as binding of various ligands to cell
surface receptors. Several previous studies have showed that sur-
amin, which bears ﬁxed-negative charges by virtue of their poly-
sulfonates, interacts with positive ectodomain of receptors and
prevents their binding of multiple cytokines and growth factors (4,
44, 45). It is likely that the binding of suramin to positively charged
molecules prevented the access and binding of Igs to its cell surface
antigens. Further detailed analysis in needed to conﬁrm or exclude
this speculation.
H. Piao et al. / Journal of Pharmacological Sciences 132 (2016) 224e234232Another alternative mechanism involved in the protective ac-
tion of suramin was direct interference of p38 activation. This ac-
tion of suramin was observed at both basal and antibody-
stimulated condition. It was also similarly observed in cells
treated with H2O2 and puromycin (46). It appeared that this effect
of suramin was a result of the direct action on cells, but not sec-
ondary to its effects on antibody binding to cell surface antigens.
Currently, the molecular mechanisms involved are unclear. p38 is
activated by its upstream kinases and deactivated by phosphatases
(37). Suramin has been reported to modulate the activities of
several phosphatases and kinases. It is highly possible that it sup-
pressed p38 phosphorylation through inhibition of its upstream
kinases or stimulation of its downstream phosphatases (47, 48).
It is worth mentioning that we also observed that suramin at
high concentration tended to interfere with LDH assay. At the
concentration of 300 mM, suramin suppressed LDH activity up to
12% (Supplementary Fig. 1). Given that suramin exerted a muchFig. 7. Suramin inhibits p38 activation at both basal and stimulated situations. (A, B) Effect of su
time intervals or different concentrations of suramin for 60 min. The cellular lysates were s
was used as loading control. (CeF) Effect of suramin on p38 activation induced by H2O2 and
lysates were subject to Western blot analysis of p38. The intensity of p38 phopshorylation
relative to untreated control (mean ± SE, n ¼ 4 in D, n ¼ 3 in F). #P < 0.01, *P < 0.05 vs. rmore potent inhibitory effect on complement-initiated LDH release
and that it also protected cells against complement-induced cell
death, as evidenced by cell shape, PI and calcein-AM staining, the
interference of suramin on LDH assay should not affect our
conclusion. As a molecule with multifaceted biological functions,
including modulation of enzyme activities and interference of
protein-to-protein interactions, it is conceivable that suramin
might also affect the reaction between cell membrane-bound IgG
and Rhodamine- or HRP-labeled secondary antibodies used in IF
staining and cellular Elisa. However, this possibility was relatively
low, because suramin was washed out prior to addition of the
labeled antibodies during the experiments.
Our ﬁndings could have great clinic and basic relevance. First, our
study indicates that suraminmight beexploited tomodulate immune
responses and prevent cell injury initiated by antibody and comple-
ment complex, such as transfusion reactions, anto-immune hemo-
lytic anemia, erythroblastosis fetalis, goodpasture's syndrome, andramin on the basal level of p38. MCs were exposed to 300 mM suramin for the indicated
ubject to Western blot analysis of the level of phosphorylated p38. Total p38 or b-actin
puromycin. MCs were exposed to 200 mM H2O2 or 3 mM puromycin for 3 h. The cellular
in C and E were shown in D and F, respectively. Data were expressed as fold induction
espective control.
H. Piao et al. / Journal of Pharmacological Sciences 132 (2016) 224e234 233antibody-dependent cell-mediated cytotoxicity (ADCC). Second, our
study provided novelmechanistic insights into the suppressive effect
of suramin on inﬂammatory cell injury. Apart from the previously
reported inhibitory effects on complement, suramin also blocked
antibodybinding to cell surface antigens andmodulated the activities
of the important cellular signaling molecule p38. Suraminmay exert
its therapeutic actions through multifaceted mechanisms. Given the
importance of p38 in control of a variety of cell responses, direct
regulation of cellular p38 activity could be an important mechanism
by which suramin exerted its therapeutic effects.
In summary, we demonstrated that suramin protected cells
from antibody/complement-induced lysis through multiple
mechanisms. Our study thus provided novel mechanistic insights
into the pharmacologic actions of suramin and suggested that
suramin may be used to treat certain immune diseases.
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